Aims: Osteogenesis imperfecta (OI) is a rare inherited disorder causing low bone density and increased fragility. Bisphosphonates (BP) are a treatment of choice for OI. Few studies have investigated the long-term effects of BP in OI patients. Thus, aim of our study was to follow up adults affected by OI to evaluate changes in metabolic, clinical situation and safety of long-term neridronic acid therapy, BP authorized for OI treatment. Study design: Longitudinal observational study. Place and duration of the Study: Department of Experimental Medicine, Section of Medical Pathophysiology, Endocrinology and Nutrition. Year: 2004 - October 2010. Methodology: 68 patients underwent clinical examination, laboratory endocrine/ metabolic, pro-inflammatory cytokines screening, ECG at baseline and every 3 months and bone mineral density evaluation, by DEXA, once a year. Results: Skeletal evaluation showed a significant increase of BMD through follow up.
Metabolic Characterization and Follow up of Adult Patients Affected by Osteogenesis Imperfecta in Long-term Treatment with Neridronic Acid / Fornari, Rachele; P., Sgro; Greco, Emanuela; Francomano, Davide; Antonio, Aversa; Marini, Mario; Lubrano, Carla; Marocco, Chiara; Conti, Francesco; Spera, Giovanni; L., Di Luigi; Lenzi, Andrea; Silvia, Migliaccio. - In: BRITISH JOURNAL OF MEDICINE AND MEDICAL RESEARCH. - ISSN 2231-0614. - ELETTRONICO. - 1:4(2011), pp. 478-485. [10.9734/bjmmr/2011/501]
Metabolic Characterization and Follow up of Adult Patients Affected by Osteogenesis Imperfecta in Long-term Treatment with Neridronic Acid
FORNARI, RACHELE;GRECO, EMANUELA;FRANCOMANO, DAVIDE;MARINI, Mario;LUBRANO, Carla;MAROCCO, CHIARA;CONTI, Francesco;SPERA, Giovanni;LENZI, Andrea;Silvia Migliaccio
2011
Abstract
Aims: Osteogenesis imperfecta (OI) is a rare inherited disorder causing low bone density and increased fragility. Bisphosphonates (BP) are a treatment of choice for OI. Few studies have investigated the long-term effects of BP in OI patients. Thus, aim of our study was to follow up adults affected by OI to evaluate changes in metabolic, clinical situation and safety of long-term neridronic acid therapy, BP authorized for OI treatment. Study design: Longitudinal observational study. Place and duration of the Study: Department of Experimental Medicine, Section of Medical Pathophysiology, Endocrinology and Nutrition. Year: 2004 - October 2010. Methodology: 68 patients underwent clinical examination, laboratory endocrine/ metabolic, pro-inflammatory cytokines screening, ECG at baseline and every 3 months and bone mineral density evaluation, by DEXA, once a year. Results: Skeletal evaluation showed a significant increase of BMD through follow up.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
